CD5 and T-cell non-Hodgkin lymphoma: The most represented aberrancies in B-cell lymphoma were MHCII- (9/17, 53%), CD3+/CD21+ (7/17, 41%), CD34+ (4/17, 24%), CD79a- (4/17, 24%), while CD3+/CD21+ (5/8, 63%), CD4-/CD8- (4/8, 50%), CD45- (4/8, 50%), CD5- (4/8, 50%) were expressed in T-cell lymphoma.